|
US2014010869A1
|
|
Formulation and manufacturing process for calcium acetate capsules
|
|
US2009170815A1
|
|
Alendronate oral liquid formulations
|
|
US2009169622A1
|
|
Delayed-release oral pharmaceutical composition for treatment of colonic disorders
|
|
US2007248564A1
|
|
Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia
|
|
US2008145422A1
|
|
Galantamine tablet formulation
|
|
US2003118641A1
|
|
Abuse-resistant sustained-release opioid formulation
|
|
WO02053186A2
|
|
Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus
|
|
WO0113886A1
|
|
Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent
|
|
WO0108661A2
|
|
Opioid sustained-released formulation
|
